Kreisl Teri N, Lassman Andrew B, Mischel Paul S, Rosen Neal, Scher Howard I, Teruya-Feldstein Julie, Shaffer David, Lis Eric, Abrey Lauren E
Neuro-Oncology Branch, National Cancer Institute, 9030 Old Georgetown Road, Bethesda, MD 20892, USA.
J Neurooncol. 2009 Mar;92(1):99-105. doi: 10.1007/s11060-008-9741-z. Epub 2008 Nov 19.
Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment.
22例复发性胶质母细胞瘤（GBM）患者接受了依维莫司和吉非替尼的前瞻性治疗，作为一项更大规模临床试验的一部分，旨在测试对哺乳动物雷帕霉素靶蛋白（mTOR）和表皮生长因子受体（EGFR）的联合抑制作用。主要终点是影像学缓解率。次要终点包括无进展生存期以及分子谱与治疗反应的相关性。36%的患者病情稳定，14%的患者部分缓解；然而，缓解并不持久，6个月时只有1例患者无进展。传统的反应标准无法很好地描述影像学变化，这意味着治疗在肿瘤内有不同的作用和/或抗血管生成作用。EGFR和PTEN状态不能明确预测治疗反应。
